| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 9 | | | |
| | | | 13 | | | |
| | | | 13 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 14 | | | |
| | | | 15 | | | |
| | | | 15 | | | |
| | | | 16 | | | |
| | | | 16 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 23 | | | |
| | | | 27 | | | |
| | | | 28 | | | |
| | | | 29 | | | |
| | | | 29 | | | |
| | | | 48 | | | |
| | | | 49 | | | |
| | | | 50 | | | |
| | | | 54 | | | |
| | | | 57 | | | |
| | | | 60 | | | |
| | | | 60 | | | |
| | | | 61 | | | |
| | | | 61 | | | |
| | | | 61 | | | |
| | | | 62 | | | |
| | | | 65 | | | |
| | | | 66 | | | |
| | | | 70 | | | |
| | | | 70 | | | |
| | | | 70 | | | |
| | | | 72 | | | |
| | | | 73 | | | |
| | | | 74 | | |
| | We provide internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies. | | |
Name
|
| |
Age
|
| |
Position
|
|
Willard H. Dere, M.D | | |
70
|
| | Director (Class I) | |
Martin Huber, M.D. | | |
64
|
| |
Director (Class I); President and Chief Executive Officer
|
|
Allene M. Diaz | | |
59
|
| | Director (Class II) | |
Andrew A. F. Hack, M.D., Ph.D. | | |
50
|
| | Director (Class II) | |
Name
|
| |
Age
|
| |
Position
|
|
Kristen M. Hege, M.D. | | |
60
|
| | Director (Class II) | |
Lawrence M. Alleva | | |
74
|
| | Director (Class III) | |
David Mott | | |
58
|
| | Chair of the Board of Directors (Class III) | |
Anna Protopapas | | |
59
|
| | Director (Class III) | |
| |
Board Diversity Matrix (as of April 26, 2024)
|
| | ||||||||||||||||
| | Total Number of Directors | | | |
8
|
| | ||||||||||||
| | | | | |
Female
|
| | |
Male
|
| | |
Non-Binary
|
| | |
Did not
Disclose Gender |
| |
| | Part I: Gender Identity | | | ||||||||||||||||
| | Directors | | | |
3
|
| | |
5
|
| | | | | | | | | |
| | Part II: Demographic Background | | | ||||||||||||||||
| | African American or Black | | | | | | | | | | | | | | | | | | |
| | Alaskan Native or Native American | | | | | | | | | | | | | | | | | | |
| | Asian | | | | | | | |
1
|
| | | | | | | | | |
| | Hispanic or Latinx | | | |
1
|
| | | | | | | | | | | | | |
| | Native Hawaiian or Pacific Islander | | | | | | | | | | | | | | | | | | |
| | White | | | |
2
|
| | |
4
|
| | | | | | | | | |
| | Two or More Races or Ethnicities | | | | | | | | | | | | | | | | | | |
| | LGBTQ+ | | | |
1
|
| | ||||||||||||
| | Did not Disclose Demographic Background | | | | | | |
Name
|
| |
Audit
Committee |
| |
Compensation
Committee |
| |
Nominating
and Corporate Governance Committee |
|
Lawrence M. Alleva
|
| |
Chair
|
| | | | |
X
|
|
Willard H. Dere, M.D.
|
| |
X
|
| | | | |
Chair
|
|
Allene M. Diaz
|
| | | | |
X
|
| | | |
Andrew A.F. Hack, M.D., Ph.D.
|
| |
X
|
| | | | | | |
Kristen M. Hege, M.D.(2)
|
| | | | |
X(1)
|
| |
X(2)
|
|
David Mott
|
| | | | |
Chair
|
| | | |
Name(1)
|
| |
Fees
Earned or Paid in Cash ($)(2) |
| |
Stock Awards
($)(3) |
| |
Option Awards
($)(4) |
| |
Total
($) |
| ||||||||||||
Lawrence M. Alleva
|
| | | | 59,000 | | | | | | 124,995 | | | | | | 124,930 | | | | | | 308,925 | | |
Willard Dere, M.D.
|
| | | | 55,500 | | | | | | 124,995 | | | | | | 124,930 | | | | | | 305,425 | | |
Allene M. Diaz
|
| | | | 45,000 | | | | | | 124,995 | | | | | | 124,930 | | | | | | 294,925 | | |
Andrew A. F. Hack, M.D., Ph.D.
|
| | | | 47,500 | | | | | | 124,995 | | | | | | 124,930 | | | | | | 297,425 | | |
Kristen M. Hege, M.D.
|
| | | | 43,500 | | | | | | 124,995 | | | | | | 124,930 | | | | | | 293,425 | | |
David Mott
|
| | | | 80,000 | | | | | | 124,995 | | | | | | 124,930 | | | | | | 329,925 | | |
Name
|
| |
Cash Fees
Paid in the Form of Equity ($) |
| |
Shares
Subject to Stock Options Granted in Respect of Cash Fees (#) |
| |
Shares of
Common Stock Granted in Respect of Cash Fees (#) |
| |||||||||
Lawrence M. Alleva
|
| | | | 58,927 | | | | | | 31,726 | | | | | | — | | |
Willard Dere, Ph.D.
|
| | | | 55,493 | | | | | | — | | | | | | 24,715 | | |
Kristen M. Hege, M.D.
|
| | | | 43,439 | | | | | | 23,075 | | | | | | — | | |
David Mott
|
| | | | 79,998 | | | | | | — | | | | | | 35,628 | | |
Name
|
| |
Age
|
| |
Position
|
|
Martin Huber, M.D. | | |
64
|
| | Chief Executive Officer and President; Director | |
Mohan Bala, Ph.D. | | |
59
|
| | Senior Vice President, Chief Development Officer | |
Alejandra Carvajal | | |
50
|
| | Senior Vice President, Chief Legal Officer | |
Brian DeSchuytner | | |
46
|
| |
Senior Vice President, Chief Operating Officer and Chief Financial Officer
|
|
Timothy B. Lowinger, Ph.D. | | |
60
|
| | Senior Vice President, Chief Science and Technology Officer | |
Tushar Misra, Ph.D. | | |
64
|
| | Senior Vice President, Chief Manufacturing Officer | |
Named Executive Officer
|
| |
Position
|
|
Martin Huber, M.D. | | | President and Chief Executive Officer; Director(1) | |
Anna Protopapas | | | Former President and Chief Executive Officer; Director (2) | |
Brian DeSchuytner | | | Senior Vice President, Chief Operating Officer and Chief Financial Officer(3) | |
Mohan Bala, Ph.D. | | | Senior Vice President, Chief Development Officer(4) | |
Alejandra Carvajal | | | Senior Vice President, Chief Legal Officer | |
Timothy B. Lowinger, Ph.D. | | | Senior Vice President, Chief Science and Technology Officer | |
Arvin Yang, M.D. | | | Former Senior Vice President, Chief Medical Officer(5) | |
|
What We Do
|
| |
What We Don’t Do
|
|
|
✓
Maintain an industry- and size-appropriate peer group for benchmarking compensation
✓
Tie cash-based incentives to achievement of Company objectives
✓
Provide a majority of compensation in long-term equity incentives with multi-year vesting schedules
✓
Provide a competitive mix of fixed (e.g., base salary) and variable (e.g., bonus) compensation
✓
Evaluate the risk profile of our pay programs
✓
Set robust executive officer and non-employee director stock ownership guidelines
✓
Maintain a comprehensive compensation recoupment (clawback) policy applicable to both cash and equity incentive compensation
✓
Consult with an independent compensation advisor
|
| |
✘
No employment arrangements that guarantee a certain compensation level or employment term
✘
No guaranteed salary increases or bonuses
✘
No single-trigger vesting in connection with a change-in-control for equity awards
✘
No special perquisites or personal benefits for executives
✘
No retirement plans other than our 401(k) and no special health or welfare benefits for executives
✘
No hedging or pledging or speculative transactions in our securities
✘
No tax gross-up provisions
|
|
| Alaunos Therapeutics, Inc. | | | Jounce Therapeutics, Inc. | |
| Arcus Biosciences, Inc. | | | Kura Oncology, Inc. | |
| Cogent Biosciences, Inc.* | | | Pieris Pharmaceuticals, Inc. | |
| Cue Biopharma, Inc. | | | Relay Therapeutics, | |
| Foghorn Therapeutics, Inc.* | | | Replimune Group, Inc. | |
| Forma Therapeutics Holdings, Inc. | | | Scholar Rock Holding Corporation | |
| IGM Biosciences, Inc. | | | Seres Therapeutics, Inc.* | |
| ImmunoGen, Inc. | | | TCR2 Therapeutics Inc. | |
| Inovio Pharmaceuticals, Inc. | | | Zymeworks, Inc. | |
| Adicet Bio, Inc.* | | | Omega Therapeutics, Inc.* | |
| Black Diamond Therapeutics, Inc.* | | | Prelude Therapeutics Incorporated* | |
| C4 Therapeutics, Inc.* | | | Scholar Rock Holding Corporation | |
| Cue Biopharma, Inc. | | | Tango Therapeutics, Inc.* | |
| Foghorn Therapeutics, Inc. | | | TScan Therapeutics, Inc.* | |
| IGM Biosciences, Inc. | | | Verastem, Inc.* | |
| Ikena Oncology, Inc.* | | | Vor Biopharma, Inc.* | |
| Inovio Pharmaceuticals, Inc. | | | Werewolf Therapeutics, Inc.* | |
| iTeos Therapeutics, Inc.* | | | Zymeworks, Inc. | |
| Monte Rosa Therapeutics, Inc.* | | | | |
Name
|
| |
2022
Annual Base Salary |
| |
2023
Annual Base Salary |
| |
%
Increase from 2022 |
| |||||||||
Martin Huber, M.D.
|
| | | | N/A | | | | | $ | 625,000 | | | |
N/A
|
| |||
Anna Protopapas
|
| | | $ | 605,000 | | | | | $ | 650,000 | | | | | | 7.4% | | |
Brian DeSchuytner
|
| | | $ | 421,303 | | | | | $ | 444,475 | | | | | | 5.5% | | |
Mohan Bala, Ph.D.
|
| | | $ | 410,000 | | | | | $ | 430,500 | | | | | | 5.0% | | |
Alejandra Carvajal
|
| | | $ | 414,000 | | | | | $ | 430,560 | | | | | | 4.0% | | |
Timothy B. Lowinger, Ph.D.
|
| | | $ | 450,036 | | | | | $ | 470,063 | | | | | | 4.5% | | |
Arvin Yang, M.D.
|
| | | $ | 527,850 | | | | | $ | 546,325 | | | | | | 3.5% | | |
|
(
|
| |
Annual
Base Salary |
| |
*
|
| |
Target Bonus
Opportunity (40%) |
| |
)
|
| |
*
|
| |
[
|
| |
(
|
| |
Corporate
Achievement Percentage (0 – 100%) |
| |
*
|
| |
75%
|
| |
)
|
| |
+
|
| |
(
|
| |
Individual
Performance Ranking Multiplier (0 – 130%) |
| |
*
|
| |
25%
|
| |
)
|
| |
]
|
| |
=
|
| |
Total
Annual Bonus Payout |
|
Goals — 1H 2023
|
| |
Potential
Base Points |
| |
Actual
Base Points |
| ||||||
UpRi | | | | | | | | | | | | | |
•
Advance UpRi development in preparation for potential future submission of a Biologics License Application, or BLA
|
| | | | 15 | | | | | | 3 | | |
•
Execute branding and medical affairs preparations for potential commercialization of UpRi, assuming approval of BLA in 2024
|
| | | | 3.75 | | | | | | 1 | | |
•
Complete enrollment objectives for our UPGRADE-A clinical trial
|
| | | | 3.75 | | | | | | 2 | | |
•
Progress our UP-NEXT Phase 3 clinical trial
|
| | | | 7.5 | | | | | | 1 | | |
Pipeline & Continued Innovation | | | | | | | | | | | | | |
•
Progress dose escalation in Phase 1 clinical trial of XMT-1660
|
| | | | 5 | | | | | | 5 | | |
•
Progress dose escalation in Phase 1 clinical trial of XMT-2056
|
| | | | 5 | | | | | | 0 | | |
•
Continue research and development work related to our preclinical product candidate pipeline and platforms, including with respect to our strategic collaborations
|
| | | | 2.5 | | | | | | 2 | | |
Corporate | | | | | | | | | | | | | |
•
Maintain a strong balance sheet and execute new business development transactions that meet our strategic objectives for our platforms and product candidates
|
| | | | 5 | | | | | | 5 | | |
•
Maintain and continue to build a strong organization
|
| | | | 2.5 | | | | | | 2 | | |
1H 2023 Subtotal | | | | | 50 | | | | | | 21 | | |
Goals — 2H 2023
|
| |
Potential
Base Points |
| |
Actual
Base Points |
| ||||||
Clinical Development | | | | | | | | | | | | | |
•
Wind-down UpRi program
|
| | | | 5 | | | | | | 5 | | |
•
Progress dose escalation in Phase 1 clinical trial of XMT-1660
|
| | | | 20 | | | | | | 18 | | |
•
Complete activities necessary to prepare to resume Phase 1 clinical trial
|
| | | | 7.5 | | | | | | 7.5 | | |
Pipeline & Continued Innovation | | | | | | | | | | | | | |
•
Continue research and development work related to our preclinical product candidate pipeline and platforms, including with respect to our strategic collaborations
|
| | | | 5 | | | | | | 5 | | |
Corporate | | | | | | | | | | | | | |
•
Maintain a strong balance sheet and execute new business development transactions that meet our strategic objectives for our platforms and product candidates
|
| | | | 7.5 | | | | | | 7.5 | | |
•
Maintain strong culture and minimize voluntary attrition
|
| | | | 5 | | | | | | 5 | | |
2H 2023 Subtotal | | | | | 50 | | | | | | 48 | | |
2023 Total | | | | | 100 | | | | | | 69 | | |
Name and Position
|
| |
Target Bonus
(% of Base Salary) |
| |
Effective
Corporate Goal Achievement |
| |
Weight of
Corporate Goal Achievement |
| |
Individual
Performance Achievement |
| |
Weight of
Individual Performance Achievement |
| |
Bonus
Amount Paid ($) |
| |
Bonus
Amount Paid (% of Target Bonus) |
| |||||||||||||||||||||
Martin Huber, M.D., President and Chief Executive Officer
|
| | | | 60% | | | | | | 96% | | | | | | 100% | | | | | | — | | | | | | — | | | | | $ | 110,466(1) | | | | | | 96% | | |
Anna Protopapas, former President and
Chief Executive Officer |
| | | | 60% | | | | | | 50% | | | | | | 100% | | | | | | — | | | | | | — | | | | | $ | 135,164(1) | | | | | | 50% | | |
Brian DeSchuytner, Senior Vice
President, Chief Operating Officer and Chief Financial Officer |
| | | | 40% | | | | | | 50% | | | | | | 75% | | | | | | 110% | | | | | | 25% | | | | | $ | 115,564 | | | | | | 65% | | |
Mohan Bala, Senior Vice President, Chief Development Officer
|
| | | | 40% | | | | | | 50% | | | | | | 75% | | | | | | 110% | | | | | | 25% | | | | | $ | 111,930 | | | | | | 65% | | |
Alejandra Carvajal, Senior Vice President, Chief Legal Officer
|
| | | | 40% | | | | | | 50% | | | | | | 75% | | | | | | 130% | | | | | | 25% | | | | | $ | 120,557 | | | | | | 70% | | |
Timothy B. Lowinger, Ph.D., Senior Vice
President, Chief Science & Technology Officer |
| | | | 40% | | | | | | 50% | | | | | | 75% | | | | | | 85% | | | | | | 25% | | | | | $ | 110,465 | | | | | | 59% | | |
Name
|
| |
Stock Options
(#)(1) |
| |
RSUs
(#)(2) |
| ||||||
Anna Protopapas
|
| | | | 562,500 | | | | | | 125,000 | | |
Brian DeSchuytner
|
| | | | 180,000 | | | | | | 40,000 | | |
Mohan Bala, Ph.D.
|
| | | | 157,500 | | | | | | 35,000 | | |
Alejandra Carvajal
|
| | | | 161,250 | | | | | | 35,833 | | |
Timothy B. Lowinger, Ph.D.
|
| | | | 168,750 | | | | | | 37,500 | | |
Arvin Yang, M.D.
|
| | | | 217,500 | | | | | | 48,333 | | |
Name
|
| |
Stock Options
(#) |
| |
RSUs
(#) |
| ||||||
Martin Huber, M.D.
|
| | | | 1,000,000(1) | | | | | | 667,000(2) | | |
Brian DeSchuytner
|
| | | | — | | | | | | 50,000(3) | | |
Mohan Bala, Ph.D.
|
| | | | — | | | | | | 50,000(3) | | |
Alejandra Carvajal
|
| | | | — | | | | | | 50,000(3) | | |
Timothy B. Lowinger, Ph.D.
|
| | | | — | | | | | | 50,000(3) | | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Stock
Awards ($)(1) |
| |
Option
Awards ($)(2) |
| |
Non-Equity
Incentive Plan Compensation ($)(3) |
| |
All
Other Compensation ($)(4) |
| |
Total
($) |
| |||||||||||||||||||||
Martin Huber, M.D.(5)
President and Chief Executive Officer |
| | | | 2023 | | | | | | 194,311 | | | | | | 880,440 | | | | | | 1,133,300 | | | | | | 110,466 | | | | | | 282,733(6) | | | | | | 2,601,249 | | |
Anna Protopapas(7)
Former President and Chief Executive Officer |
| | | | 2023 | | | | | | 448,333 | | | | | | 757,500 | | | | | | 3,019,207 | | | | | | — | | | | | | 224,969(8) | | | | | | 4,450,009 | | |
| | | 2022 | | | | | | 605,000 | | | | | | 420,760 | | | | | | 1,377,747 | | | | | | 435,600 | | | | | | 7,000 | | | | | | 2,846,107 | | | ||
| | | 2021 | | | | | | 569,250 | | | | | | 1,792,650 | | | | | | 5,632,504 | | | | | | 276,086 | | | | | | 7,000 | | | | | | 8,277,490 | | | ||
Brian DeSchuytner
Senior Vice President, Chief Operating Officer and Chief Financial Officer |
| | | | 2023 | | | | | | 444,475 | | | | | | 299,400 | | | | | | 871,776 | | | | | | 115,564 | | | | | | 7,000 | | | | | | 1,738,215 | | |
| | | 2022 | | | | | | 421,303 | | | | | | 157,000 | | | | | | 514,170 | | | | | | 198,012 | | | | | | 7,000 | | | | | | 1,297,485 | | | ||
| | | 2021 | | | | | | 405,099 | | | | | | 527,250 | | | | | | 1,656,619 | | | | | | 158,394 | | | | | | 7,000 | | | | | | 2,754,362 | | | ||
Mohan Bala, Ph.D.(9)
Senior Vice President, Chief Development Officer |
| | | | 2023 | | | | | | 430,500 | | | | | | 269,100 | | | | | | 762,804 | | | | | | 111,930 | | | | | | 7,000 | | | | | | 1,581,334 | | |
Alejandra Carvajal(10)
Senior Vice President, Chief Legal Officer |
| | | | 2023 | | | | | | 430,560 | | | | | | 274,148 | | | | | | 780,966 | | | | | | 120,557 | | | | | | 7,000 | | | | | | 1,613,231 | | |
| | | 2022 | | | | | | 414,000 | | | | | | 62,800 | | | | | | 205,668 | | | | | | 192,510 | | | | | | — | | | | | | 874,978 | | | ||
| | | 2021 | | | | | | 274,359 | | | | | | 449,970 | | | | | | 1,346,209 | | | | | | 107,712 | | | | | | — | | | | | | 2,178,250 | | | ||
Timothy B. Lowinger, Ph.D.
Senior Vice President, Chief Science and Technology Officer |
| | | | 2023 | | | | | | 470,063 | | | | | | 284,250 | | | | | | 817,290 | | | | | | 110,465 | | | | | | 7,000 | | | | | | 1,689,068 | | |
| | | 2022 | | | | | | 450,036 | | | | | | 120,369 | | | | | | 394,197 | | | | | | 209,267 | | | | | | 7,000 | | | | | | 1,180,869 | | | ||
| | | 2021 | | | | | | 423,563 | | | | | | 615,132 | | | | | | 1,932,722 | | | | | | 167,731 | | | | | | 7,000 | | | | | | 3,146,148 | | | ||
Arvin Yang, M.D.(11)
Former Senior Vice President, Chief Medical Officer |
| | | | 2023 | | | | | | 409,744 | | | | | | 292,898 | | | | | | 1,053,396 | | | | | | — | | | | | | 156,314(12) | | | | | | 1,912,352 | | |
| | | 2022 | | | | | | 527,850 | | | | | | 177,931 | | | | | | 582,726 | | | | | | 245,450 | | | | | | 7,000 | | | | | | 1,540,957 | | | ||
| | | 2021 | | | | | | 510,000 | | | | | | — | | | | | | — | | | | | | 201,960 | | | | | | 157,000(13) | | | | | | 868,960 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Year-end value
of $100 invested on 12/31/2019 in: |
| | | | | | | |||||||||
Year
|
| |
Summary
Compensation Table Total for the First PEO(1) ($) |
| |
Summary
Compensation Table Total for the Second PEO(2) ($) |
| |
Compensation
Actually Paid to the First PEO(1)(3)(4) ($) |
| |
Compensation
Actually Paid to the Second PEO(2)(3)(4) ($) |
| |
Average
Summary Compensation Table Total for Non-PEO NEOs(5) ($) |
| |
Average
Compensation Actually Paid to Non-PEO NEOs(3)(4)(5) ($) |
| |
MRSN
Total Shareholder Return ($) |
| |
Peer
Group Total Shareholder Return(6) ($) |
| |
Net Loss
(in millions) ($) |
| |||||||||||||||||||||||||||
2023
|
| | | | 2,601,249 | | | | | | 4,450,009 | | | | | | 4,255,366 | | | | | | (353,115) | | | | | | 1,706,840 | | | | | | 495,789 | | | | | | 40.49 | | | | | | 118.87 | | | | | | (171.7) | | |
2022
|
| | | | N/A | | | | | | 2,846,107 | | | | | | N/A | | | | | | 2,407,467 | | | | | | 1,223,572 | | | | | | 1,079,403 | | | | | | 102.27 | | | | | | 113.65 | | | | | | (204.2) | | |
2021
|
| | | | N/A | | | | | | 8,277,490 | | | | | | N/A | | | | | | (6,779,152) | | | | | | 2,409,043 | | | | | | (1,407,347) | | | | | | 108.55 | | | | | | 126.45 | | | | | | (170.1) | | |
2020
|
| | | | N/A | | | | | | 2,537,911 | | | | | | N/A | | | | | | 16,408,361 | | | | | | 2,005,448 | | | | | | 6,137,850 | | | | | | 464.40 | | | | | | 126.42 | | | | | | (88.0) | | |
| | |
2023
|
| |
2022
|
| |
2021
|
| |
2020
|
| ||||||||||||||||||||||||||||||||||||||||||
| | |
First
PEO ($) |
| |
Second
PEO ($) |
| |
Average
Non-PEO NEOs ($) |
| |
PEO
($) |
| |
Average
Non-PEO NEOs ($) |
| |
PEO
($) |
| |
Average
Non-PEO NEOs ($) |
| |
PEO
($) |
| |
Average
Non-PEO NEOs ($) |
| |||||||||||||||||||||||||||
Total Compensation from Summary Compensation Table
|
| | | | 2,601,249 | | | | | | 4,450,009 | | | | | | 1,706,840 | | | | | | 2,846,107 | | | | | | 1,223,572 | | | | | | 8,277,490 | | | | | | 2,409,043 | | | | | | 2,537,911 | | | | | | 2,005,448 | | |
Adjustments for Equity Awards | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Adjustment for grant date values in the Summary Compensation Table
|
| | | | (2,013,740) | | | | | | (3,776,707) | | | | | | (1,141,206) | | | | | | (1,798,507) | | | | | | (553,715) | | | | | | (7,425,154) | | | | | | (1,981,419) | | | | | | (1,656,411) | | | | | | (1,550,241) | | |
Year-end fair value of unvested awards granted in the current year
|
| | | | 3,533,476 | | | | | | 510,197 | | | | | | 347,755 | | | | | | 1,441,729 | | | | | | 443,870 | | | | | | 1,538,348 | | | | | | 430,621 | | | | | | 7,965,820 | | | | | | 3,341,447 | | |
Year-over-year difference of year-end fair values for unvested awards granted in prior years
|
| | | | — | | | | | | (643,200) | | | | | | (220,779) | | | | | | (196,374) | | | | | | (58,449) | | | | | | (6,105,508) | | | | | | (1,108,788) | | | | | | 5,655,169 | | | | | | 1,717,834 | | |
Fair values at vest date for awards granted and vested in current year
|
| | | | 31,811 | | | | | | 229,104 | | | | | | 54,374 | | | | | | 226,105 | | | | | | 69,615 | | | | | | 567,422 | | | | | | 99,283 | | | | | | 822,260 | | | | | | 215,235 | | |
| | |
2023
|
| |
2022
|
| |
2021
|
| |
2020
|
| ||||||||||||||||||||||||||||||||||||||||||
| | |
First
PEO ($) |
| |
Second
PEO ($) |
| |
Average
Non-PEO NEOs ($) |
| |
PEO
($) |
| |
Average
Non-PEO NEOs ($) |
| |
PEO
($) |
| |
Average
Non-PEO NEOs ($) |
| |
PEO
($) |
| |
Average
Non-PEO NEOs ($) |
| |||||||||||||||||||||||||||
Difference in fair values between prior year-end fair values and vest date fair values for awards granted in prior years
|
| | | | 102,570 | | | | | | (281,491) | | | | | | (84,633) | | | | | | (111,593) | | | | | | (45,490) | | | | | | (3,631,751) | | | | | | (661,387) | | | | | | 1,083,613 | | | | | | 408,127 | | |
Forfeitures during current year equal to prior year-end fair value
|
| | | | — | | | | | | (841,027) | | | | | | (166,562) | | | | | | — | | | | | | — | | | | | | — | | | | | | (594,699) | | | | | | — | | | | | | — | | |
Total Adjustments for Equity Awards
|
| | | | 1,654,117 | | | | | | (4,803,124) | | | | | | (1,211,051) | | | | | | (438,640) | | | | | | (144,169) | | | | | | (15,056,642) | | | | | | (3,816,390) | | | | | | 13,870,451 | | | | | | 4,132,402 | | |
Compensation Actually Paid (as calculated)
|
| | | | 4,255,366 | | | | | | (353,115) | | | | | | 495,789 | | | | | | 2,407,467 | | | | | | 1,079,403 | | | | | | (6,779,152) | | | | | | (1,407,347) | | | | | | 16,408,361 | | | | | | 6,137,850 | | |
|
Name
|
| |
Grant
date |
| |
Estimated future
payouts under non-equity incentive plan awards |
| |
All other
stock awards: Number of shares of stock or units (#) |
| |
All other
option awards: Number of securities underlying options (#) |
| |
Exercise or
base price of option awards ($/share) |
| |
Grant date
fair value of stock and option awards ($)(1) |
| ||||||||||||||||||||||||||||||
|
Threshold
($) |
| |
Target
($) |
| |
Maximum
($) |
| |||||||||||||||||||||||||||||||||||||||||
Martin Huber, M.D.
|
| | | | —(2) | | | | | | — | | | | | | 375,000 | | | | | | 375,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 4/3/2023(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,375 | | | | | | 4.25 | | | | | | 10,994 | | | ||
| | | 6/8/2023(4) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 18,355 | | | | | | 8.64 | | | | | | 124,930 | | | ||
| | | 6/8/2023(5) | | | | | | — | | | | | | — | | | | | | — | | | | | | 14,467 | | | | | | — | | | | | | — | | | | | | 124,995 | | | ||
| | | 7/3/2023(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 4,477 | | | | | | 3.42 | | | | | | 12,241 | | | ||
| | | 9/11/2023(6) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,000,000 | | | | | | 1.32 | | | | | | 1,258,230 | | | ||
| | | 9/11/2023(7) | | | | | | — | | | | | | — | | | | | | — | | | | | | 667,000 | | | | | | — | | | | | | — | | | | | | 880,440 | | | ||
| | | 10/2/2023(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,102 | | | | | | 1.26 | | | | | | 9,551 | | | ||
Anna Protopapas
|
| | | | —(2) | | | | | | — | | | | | | 390,000 | | | | | | 390,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 1/13/2023(8) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 562,500 | | | | | | 6.06 | | | | | | 2,724,300 | | | ||
| | | 1/13/2023(9) | | | | | | — | | | | | | — | | | | | | — | | | | | | 125,000 | | | | | | — | | | | | | — | | | | | | 779,469 | | | ||
| | | 9/11/2023(10) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 16,643 | | | | | | 1.32 | | | | | | 18,645 | | | ||
| | | 9/11/2023(11) | | | | | | — | | | | | | — | | | | | | — | | | | | | 16,643 | | | | | | — | | | | | | — | | | | | | 21,969 | | | ||
| | | 9/11/2023(12) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 748,366 | | | | | | 1.53 | | | | | | 218,523 | | | ||
| | | 9/11/2023(12) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 158,958 | | | | | | 4.10 | | | | | | 55,317 | | | ||
| | | 9/11/2023(12) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 66,666 | | | | | | 6.98 | | | | | | 21,066 | | | ||
Brian DeSchuytner
|
| | | | —(2) | | | | | | — | | | | | | 177,790 | | | | | | 191,124 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 1/13/2023(8) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 180,000 | | | | | | 6.06 | | | | | | 871,776 | | | ||
| | | 1/13/2023(9) | | | | | | — | | | | | | — | | | | | | — | | | | | | 40,000 | | | | | | — | | | | | | — | | | | | | 242,400 | | | ||
| | | 9/5/2023(13) | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | — | | | | | | — | | | | | | 57,000 | | | ||
Mohan Bala, Ph.D.
|
| | | | —(2) | | | | | | — | | | | | | 172,200 | | | | | | 185,115 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 1/13/2023(8) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 157,500 | | | | | | 6.06 | | | | | | 762,804 | | | ||
| | | 1/13/2023(9) | | | | | | — | | | | | | — | | | | | | — | | | | | | 35,000 | | | | | | — | | | | | | — | | | | | | 212,100 | | | ||
| | | 9/5/2023(13) | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | — | | | | | | — | | | | | | 57,000 | | | ||
Alejandra Carvajal
|
| | | | —(2) | | | | | | — | | | | | | 172,224 | | | | | | 185,141 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 1/13/2023(8) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 161,250 | | | | | | 6.06 | | | | | | 780,966 | | | ||
| | | 1/13/2023(9) | | | | | | — | | | | | | — | | | | | | | | | | | | 35,833 | | | | | | — | | | | | | — | | | | | | 217,148 | | | ||
| | | 9/5/2023(13) | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | — | | | | | | — | | | | | | 57,000 | | | ||
Timothy B. Lowinger, Ph.D.
|
| | | | —(2) | | | | | | — | | | | | | 188,025 | | | | | | 202,127 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 1/13/2023(8) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 168,750 | | | | | | 6.06 | | | | | | 817,290 | | | ||
| | | 1/13/2023(9) | | | | | | — | | | | | | — | | | | | | — | | | | | | 37,500 | | | | | | — | | | | | | — | | | | | | 227,250 | | | ||
| | | 9/5/2023(13) | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | — | | | | | | — | | | | | | 57,000 | | | ||
Arvin Yang, M.D.
|
| | | | —(2) | | | | | | — | | | | | | 218,530 | | | | | | 234,920 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 1/13/2023(8) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 217,500 | | | | | | 6.06 | | | | | | 1,053,396 | | | ||
| | | 1/13/2023(9) | | | | | | — | | | | | | — | | | | | | — | | | | | | 48,333 | | | | | | — | | | | | | — | | | | | | 292,898 | | |
| | |
Option Awards
|
| | | | | | | |
Stock Awards
|
| ||||||||||||||||||||||||
Name
|
| |
Number of
securities underlying unexercised options exercisable (#) |
| |
Number of
securities underlying unexercised options unexercisable (#) |
| |
Option
exercise price ($/share) |
| |
Option
expiration date |
| |
Number
of Shares or Units of Stock that Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested(1) ($) |
| ||||||||||||||||||
Martin Huber, M.D.
|
| | | | 48,096 | | | | | | — | | | | | | 8.57 | | | | | | 4/12/2030 | | | | | | | | | | | | | | |
| | | 2,490 | | | | | | — | | | | | | 21.09 | | | | | | 1/14/2031 | | | | | | | | | | | | | | | ||
| | | 25,050 | | | | | | — | | | | | | 14.90 | | | | | | 6/10/2031 | | | | | | | | | | | | | | | ||
| | | 10,185 | | | | | | — | | | | | | 6.44 | | | | | | 1/2/2032 | | | | | | | | | | | | | | | ||
| | | 45,000 | | | | | | — | | | | | | 3.62 | | | | | | 6/8/2032 | | | | | | | | | | | | | | | ||
| | | 3,375 | | | | | | — | | | | | | 4.25 | | | | | | 4/2/2033 | | | | | | | | | | | | | | | ||
| | | — | | | | | | 18,355(2) | | | | | | 8.64 | | | | | | 6/7/2033 | | | | | | | | | | | | | | | ||
| | | 4,477 | | | | | | — | | | | | | 3.42 | | | | | | 7/2/2033 | | | | | | | | | | | | | | | ||
| | | — | | | | | | 1,000,000(3) | | | | | | 1.32 | | | | | | 9/10/2033 | | | | | | | | | | | | | | | ||
| | | 9,102 | | | | | | — | | | | | | 1.26 | | | | | | 10/1/2033 | | | | | | | | | | | | | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 667,000(4) | | | | | | 1,547,440 | | | ||
Anna Protopapas
|
| | | | 748,366 | | | | | | — | | | | | | 1.53 | | | | | | 5/7/2025 | | | | | | | | | | |||||
| | | 158,958 | | | | | | — | | | | | | 4.10 | | | | | | 8/29/2026 | | | | | | | | | | | | | | | ||
| | | 66,666 | | | | | | — | | | | | | 6.98 | | | | | | 3/13/2027 | | | | | | | | | | | | | | | ||
| | | 200,000 | | | | | | — | | | | | | 14.23 | | | | | | 2/1/2028 | | | | | | | | | | | | | | | ||
| | | 217,500 | | | | | | — | | | | | | 3.51 | | | | | | 1/22/2029 | | | | | | | | | | | | | | | ||
| | | 298,828 | | | | | | 19,922(5) | | | | | | 6.16 | | | | | | 1/14/2030 | | | | | | | | | | | | | | | ||
| | | 131,884 | | | | | | 169,566(6)(7) | | | | | | 6.28 | | | | | | 1/13/2032 | | | | | | | | | | | | | | | ||
| | | 105,469 | | | | | | 457,031(6)(8) | | | | | | 6.06 | | | | | | 1/12/2033 | | | | | | | | | | | | | | | ||
| | | — | | | | | | 16,643(6)(9) | | | | | | 1.32 | | | | | | 9/10/2033 | | | | | | | | | | | | | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 17,708(10) | | | | | | 41,083 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 42,500(6)(11) | | | | | | 98,600 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 50,250(6)(12) | | | | | | 116,580 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 125,000(6)(13) | | | | | | 290,000 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 16,643(14) | | | | | | 38,612 | | | ||
Brian DeSchuytner
|
| | | | 240,000 | | | | | | — | | | | | | 3.99 | | | | | | 7/9/2029 | | | | | | | | | | | | | | |
| | | 66,796 | | | | | | 4,454(5) | | | | | | 6.16 | | | | | | 1/14/2030 | | | | | | | | | | | | | | | ||
| | | 77,343 | | | | | | 35,157(15) | | | | | | 21.09 | | | | | | 1/14/2031 | | | | | | | | | | | | | | | ||
| | | 49,218 | | | | | | 63,282(7) | | | | | | 6.28 | | | | | | 1/13/2032 | | | | | | | | | | | | | | | ||
| | | 33,750 | | | | | | 146,250(8) | | | | | | 6.06 | | | | | | 1/12/2033 | | | | | | | | | | | | | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 3,958(10) | | | | | | 9,183 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 12,500(11) | | | | | | 29,000 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 18,750(12) | | | | | | 43,500 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 40,000(13) | | | | | | 92,800 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 50,000(16) | | | | | | 116,000 | | | ||
Mohan Bala, Ph.D.
|
| | | | 56,250 | | | | | | 56,250(17) | | | | | | 8.63 | | | | | | 10/24/2031 | | | | | | | | | | | | | | |
| | | 29,531 | | | | | | 127,969(8) | | | | | | 6.06 | | | | | | 1/12/2033 | | | | | | | | | | | | | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 12,500(18) | | | | | | 29,000 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 35,000(13) | | | | | | 81,200 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 50,000(16) | | | | | | 116,000 | | |
| | |
Option Awards
|
| | | | | | | |
Stock Awards
|
| ||||||||||||||||||||||||
Name
|
| |
Number of
securities underlying unexercised options exercisable (#) |
| |
Number of
securities underlying unexercised options unexercisable (#) |
| |
Option
exercise price ($/share) |
| |
Option
expiration date |
| |
Number
of Shares or Units of Stock that Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested(1) ($) |
| ||||||||||||||||||
Alejandra Carvajal
|
| | | | 70,313 | | | | | | 42,187(19) | | | | | | 16.98 | | | | | | 4/25/2031 | | | | | | | | | | | | | | |
| | | 19,688 | | | | | | 25,312(7) | | | | | | 6.28 | | | | | | 1/13/2032 | | | | | | | | | | | | | | | ||
| | | 30,234 | | | | | | 131,016(8) | | | | | | 6.06 | | | | | | 1/12/2033 | | | | | | | | | | | | | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 7,500(12) | | | | | | 17,400 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 35,833(13) | | | | | | 83,133 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 50,000(16) | | | | | | 116,000 | | | ||
Timothy B. Lowinger, Ph.D.
|
| | | |
103,868 |
| | | | |
— |
| | | | |
1.53 |
| | | | |
6/11/2025 |
| | | | | | | | | | | | | |
| | | 45,854 | | | | | | — | | | | | | 4.10 | | | | | | 8/29/2026 | | | | | | | | | | | | | | | ||
| | | 56,884 | | | | | | — | | | | | | 14.23 | | | | | | 2/1/2028 | | | | | | | | | | | | | | | ||
| | | 28,128 | | | | | | — | | | | | | 3.51 | | | | | | 1/22/2029 | | | | | | | | | | | | | | | ||
| | | 91,291 | | | | | | 8,907(5) | | | | | | 6.16 | | | | | | 1/14/2030 | | | | | | | | | | | | | | | ||
| | | 90,234 | | | | | | 41,016(15) | | | | | | 21.09 | | | | | | 1/14/2031 | | | | | | | | | | | | | | | ||
| | | 37,734 | | | | | | 48,516(7) | | | | | | 6.28 | | | | | | 1/13/2032 | | | | | | | | | | | | | | | ||
| | | 31,641 | | | | | | 137,109(8) | | | | | | 6.06 | | | | | | 1/12/2033 | | | | | | | | | | | | | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 7,916(10) | | | | | | 18,365 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 14,583(11) | | | | | | 33,833 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 14,375(12) | | | | | | 33,350 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 37,500(13) | | | | | | 87,000 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 50,000(16) | | | | | | 116,000 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||
Name
|
| |
Number of
shares acquired on exercise (#) |
| |
Value
realized on exercise ($) |
| |
Number of
shares acquired on vesting (#) |
| |
Value
realized on vesting(1) ($) |
| ||||||||||||
Martin Huber, M.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Anna Protopapas
|
| | | | — | | | | | | — | | | | | | 55,708 | | | | | | 337,590 | | |
Brian DeSchuytner
|
| | | | — | | | | | | — | | | | | | 16,458 | | | | | | 99,735 | | |
Mohan Bala, Ph.D.
|
| | | | — | | | | | | — | | | | | | 6,250 | | | | | | 6,938 | | |
Alejandra Carvajal
|
| | | | — | | | | | | — | | | | | | 15,750 | | | | | | 66,693 | | |
Timothy B. Lowinger, Ph.D.
|
| | | | — | | | | | | — | | | | | | 20,001 | | | | | | 121,206 | | |
Arvin Yang, M.D.
|
| | | | — | | | | | | — | | | | | | 7,084 | | | | | | 42,929 | | |
Name
|
| |
Cash
Severance Benefits(1) ($) |
| |
COBRA
Premiums(2) ($) |
| |
Value of
Accelerated Equity(3) ($) |
| |
Incremental
Fair Value of Modified Equity Awards(4) ($) |
| |
Total(5)
($) |
| |||||||||||||||
Martin Huber, M.D. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Termination without Cause or resignation for
Good Reason |
| | | | 625,000 | | | | | | 18,578 | | | | | | — | | | | | | — | | | | | | 643,578 | | |
Change of Control
|
| | | | — | | | | | | — | | | | | | 42,584(6) | | | | | | — | | | | | | 42,584 | | |
Termination without Cause or resignation for
Good Reason on or within 12 months following Change in Control |
| | | | 1,000,000 | | | | | | 27,867 | | | | | | 3,910,024 | | | | | | — | | | | | | 4,937,891 | | |
Anna Protopapas | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Retirement
|
| | | | 135,164 | | | | | | — | | | | | | — | | | | | | 294,907 | | | | | | 430,071 | | |
Change of Control
|
| | | | — | | | | | | — | | | | | | 77,224(6) | | | | | | — | | | | | | 77,224 | | |
Brian DeSchuytner | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Termination without Cause or resignation for
Good Reason |
| | | | 333,356 | | | | | | 6,629 | | | | | | — | | | | | | — | | | | | | 339,985 | | |
Termination without Cause or resignation for
Good Reason on or within 12 months following Change in Control |
| | | | 622,265 | | | | | | 8,839 | | | | | | 868,494 | | | | | | — | | | | | | 1,499,598 | | |
Alejandra Carvajal | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Termination other than for Disqualifying Conduct or resignation for Good Reason
|
| | | | 322,920 | | | | | | 18,958 | | | | | | — | | | | | | — | | | | | | 341,878 | | |
Termination other than for Disqualifying
Conduct or resignation for Good Reason on or within 12 months following Change in Control |
| | | | 602,784 | | | | | | 25,277 | | | | | | 677,087 | | | | | | — | | | | | | 1,305,148 | | |
Timothy B. Lowinger, Ph.D. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Termination without Cause or resignation for
Good Reason |
| | | | 352,547 | | | | | | 18,958 | | | | | | — | | | | | | — | | | | | | 371,505 | | |
Termination without Cause or resignation for
Good Reason on or within 12 months following Change in Control |
| | | | 658,088 | | | | | | 25,277 | | | | | | 835,019 | | | | | | — | | | | | | 1,518,384 | | |
Arvin Yang, M.D. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Termination other than for Disqualifying Conduct or resignation for Good Reason
|
| | | | 409,744 | | | | | | 18,958 | | | | | | — | | | | | | — | | | | | | 428,701 | | |
Plan Category
|
| |
Number of
securities to be issued upon exercise of outstanding options and rights (a) |
| |
Weighted
average exercise price of outstanding options and rights (b)(1) |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)(2) |
| |||||||||
Equity compensation plans approved by security holders
|
| | | | 13,513,828(3) | | | | | $ | 7.25 | | | | | | 2,422,078 | | |
Equity compensation plans not approved by security holders
|
| | | | 1,208,658(4) | | | | | $ | 9.52 | | | | | | 1,170,752 | | |
Total
|
| | | | 14,722,486 | | | | | $ | 7.42 | | | | | | 3,592,830(5) | | |
Name and address of beneficial owner
|
| |
Number of shares
beneficially owned |
| |
Percentage of shares
beneficially owned |
| ||||||
5% or greater stockholders: | | | | | | | | | | | | | |
Entities affiliated with EcoR1 Capital, LLC(1)
|
| | | | 19,364,688 | | | | | | 15.8% | | |
Entities affiliated with Venrock Healthcare Capital Partners III, L.P.(2)
|
| | | | 11,328,000 | | | | | | 9.3% | | |
Entities affiliated with Balyasny Asset Management L.P.(3)
|
| | | | 9,698,673 | | | | | | 7.9% | | |
Entities affiliated with Bain Capital Life Sciences(4)
|
| | | | 8,663,673 | | | | | | 7.1% | | |
Blackrock, Inc.(5)
|
| | | | 7,844,282 | | | | | | 6.4% | | |
SilverArc Capital Management, LLC(6)
|
| | | | 6,420,136 | | | | | | 5.2% | | |
The Vanguard Group, Inc.(7)
|
| | | | 6,237,588 | | | | | | 5.1% | | |
Directors and named executive officers: | | | | | | | | | | | | | |
Lawrence M. Alleva(8)
|
| | | | 250,353 | | | | | | * | | |
Willard H. Dere, M.D.(9)
|
| | | | 222,658 | | | | | | * | | |
Allene M. Diaz(10)
|
| | | | 127,513 | | | | | | * | | |
Andrew A. F. Hack, M.D., Ph.D.(11)
|
| | | | 8,876,933 | | | | | | 7.2% | | |
Kristen M. Hege, M.D.(12)
|
| | | | 250,156 | | | | | | * | | |
Martin Huber, M.D.(13)
|
| | | | 178,575 | | | | | | * | | |
David Mott(14)
|
| | | | 805,556 | | | | | | * | | |
Anna Protopapas(15)
|
| | | | 2,509,889 | | | | | | 2.0% | | |
Mohan Bala, Ph.D.(16)
|
| | | | 149,989 | | | | | | * | | |
Alejandra Carvajal(17)
|
| | | | 201,545 | | | | | | * | | |
Brian DeSchuytner(18)
|
| | | | 593,104 | | | | | | * | | |
Timothy B. Lowinger, Ph.D.(19)
|
| | | | 756,213 | | | | | | * | | |
Arvin Yang, M.D.
|
| | | | 30,821 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(20)
|
| | | | 15,085,121 | | | | | | 11.8% | | |
Fee Category
|
| |
2023
|
| |
2022
|
| ||||||
Audit Fees(1)
|
| | | $ | 889,483 | | | | | $ | 976,680 | | |
Audit-Related Fees(2)
|
| | | $ | — | | | | | $ | 57,040 | | |
Tax Fees(3)
|
| | | $ | 73,475 | | | | | $ | 43,351 | | |
All Other Fees
|
| | | $ | — | | | | | $ | — | | |
Total Fees
|
| | | $ | 962,958 | | | | | $ | 1,077,071 | | |
| | | |
Members of the Audit Committee of Mersana Therapeutics, Inc.
Lawrence M. Alleva, Chair Willard H. Dere Andrew A. F. Hack |
|